A phase I/IIa study of the mRNA based cancer vaccine CV9103 prepared with the RNActive technology results in distinctly longer survival than predicted by the Halabi Nomogram which correlates with the induction of antigen-specific immune responses

Na minha lista:
Detalhes bibliográficos
Main Authors: Kallen, Karl-Josef, Gnad-Vogt, Ulrike, Scheel, Birgit, Rippin, Gerd, Stenzl, Arnulf
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2013
Assuntos:
Poster Presentation
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3991276/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/2051-1426-1-S1-P219
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados